Stereotactic Body Radiation Therapy (SBRT) is used to treat cancers using substantially higher doses of radiation than conventional radiotherapy. This technology is able to deliver higher doses of radiation to a tumour, while limiting the dose of radiation to nearby normal tissues.
The drugs used in this study are Ipilimumab (Yervoy®) and Nivolumab (Opdivo®), which are immunotherapy drugs that work by reactivating the body’s own immune response to target and destroy cancer cells. In combination, Ipilimumab and Nivolumab are Health Canada-approved for the treatment of advanced kidney cancer.
This study will investigate the safety and effectiveness of combining SBRT with Ipilimumab and Nivolumab. Specifically, the researchers will test whether SBRT can improve a patient’s response to treatment with Ipilimumab and Nivolumab.
Patients on this trial will be randomly assigned to one of two groups:
1. Ipilimumab and Nivolumab only
2. SBRT followed by Ipilimumab and Nivolumab
- All subtypes eligible
- No prior systematic therapy is permitted
- Cancer must have spread beyond the kidney
- Cancer cannot be removed by surgery
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreCross Cancer Institute||Principal InvestigatorDr. Naveen Basappa||LocationEdmonton, AB||Trial StatusNot Yet Recruiting|
|Hospital / Cancer CentreJuravinski Cancer Centre||Principal InvestigatorDr. Aly-Khan Lalani||LocationHamilton, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreGrand River Regional Cancer Centre||Principal Investigator||LocationKitchener, ON||Trial StatusNot Yet Recruiting|
|Hospital / Cancer CentreLondon Regional Cancer Centre||Principal InvestigatorDr. Eric Winquist||LocationLondon, ON||Trial StatusNot Yet Recruiting|
|Hospital / Cancer CentreThe Ottawa Regional Cancer Centre||Principal InvestigatorDr. Scott Morgan||LocationOttawa, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreSunnybrook Health Sciences Centre- Odette Cancer Centre||Principal InvestigatorDr. William Chu||LocationToronto, ON||Trial StatusRecruiting|